Navigation Links
Although NeurogesX/Astellas's Qutenza is Only Approved for Postherpetic Neuralgia, Surveyed U.S. Physicians are Likely to Prescribe It for All Neuropathic Pain Types
Date:10/6/2010

BURLINGTON, Mass., Oct. 6 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, although NeurogesX/Astellas's Qutenza is only approved for postherpetic neuralgia, surveyed U.S. physicians are likely to prescribe the drug for all neuropathic pain types. When asked to assume that patients suffering from other forms of neuropathic pain would be reimbursed for the cost of Qutenza treatment, 43 percent of clinicians indicate that they are very likely to use the drug for neuropathic cancer pain, 42 percent said they are very likely to use it for painful diabetic neuropathy and 38 percent said they are very likely to use it for neuropathic back pain.

The new U.S. Physician & Payer Forum report entitled Clinician and Payer Attitudes to Novel Therapies for Neuropathic Pain: How Much Will Cost and other Differentiating Features Influence Use of New Therapies? finds that surveyed clinicians estimate that 44 percent of their use of Qutenza has been for patients with postherpetic neuralgia while only 17 percent indicate that their use of Qutenza was strictly for this patient population.

The report also finds that physicians intending to prescribe Ortho-McNeil's Nucynta will do so for all forms of neuropathic pain, regardless of physician specialty. PCPs, neurologists and pain specialists expect that between 22 and 26 percent of Nucynta prescriptions will be for patients with neuropathic back pain. PCPs, neurologists and pain specialists also expect that between 16 and 28 percent of Nucynta prescriptions will be for patients with painful diabetic neuropathy.

The survey findings also reveal that PCPs and neurologists prescribe Pfizer's Neurontin much more frequently than Pfizer's Lyrica—both antiepileptic dugs—whereas pain specialists use Lyrica more frequently than Neurontin.

"Seventy-one percent of surveyed PCPs and 61 percent of pain specialists prescribe Neurontin more frequently than Lyrica," said Decision Resources Analyst Sami Fam, Ph.D. "However, nearly half of surveyed pain specialists indicate that they prescribe Lyrica more frequently than Neurontin while only 38 percent of pain specialists prescribe Neurontin more frequently than Lyrica."

The report also finds that, among key emerging brands for the treatment of neuropathic pain, Pfizer's Tanezumab is at the greatest risk of not being reimbursed, according to surveyed managed care organizations (MCOs). Nearly one-half of surveyed MCOs indicated that they are unlikely to reimburse tanezumab. This response may be attributed to the drug's expected high cost and its emerging safety concerns.

The report is based on a U.S. survey of 50 pain specialists, 52 primary care physicians, 54 neurologists and 20 MCO pharmacy directors.

About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision Resources, Inc.Christopher Comfort781-993-2597 ccomfort@dresources.com
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NeurogesX Receives FDA Approval of Qutenza(TM) (capsaicin) 8% Patch for Treatment of Postherpetic Neuralgia (PHN)
2. NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study
3. NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
4. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
5. FDA Orders Halt to Marketing of Unapproved Single-Ingredient Oral Colchicine
6. Apligraf® Approved by Saudi Food and Drug Authority for Treatment of Chronic Wounds
7. Hoviones TwinCaps(R) Dry-powder Inhaler Approved in Japan as Part of Inavir(R) Influenza Treatment
8. Ambry Genetics Announces the Addition of Illumina HiSeq 2000 and First 510(K) Approved BeadXpress® to Its Sequencing and Genotyping Capabilities
9. ETC Biomedical Systems Offers New FDA Approved Hyperbaric Oxygen Therapy (HBOT) Medical Device
10. NABP Grants First Approved e-Advertiser Status to Pharmahelper.com, QC Supply, and Kerr Drug
11. Circadin is Approved in the EU for Treatment of Primary Insomnia in Patients Aged 55 or Over for up to 3 Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2017)... 1, 2017 Nutriceutical Holdings (NH), parent company ... (VRS), and KD Pharma Group have decided to join ... KD Pharma Group. KD Pharma Group will become the ... acquire the entire company. "We believe we ... committed to growing the NH companies by providing us ...
(Date:5/26/2017)... -- Endo International plc (NASDAQ: ENDP ) announced today ... the Company in a fireside chat at Goldman Sachs, 38 ... 2017 at 10:40 a.m. PT / 1:40 p.m. ET. The ... Rancho Palos Verdes, CA. A live ... on the Company,s website at http://www.endo.com/investors/overview . Participants should ...
(Date:5/22/2017)... MAITLAND, Fla. , May 22, 2017 /PRNewswire/ ... industry as a whole continue to make the ... evidence becomes increasingly important for ensuring positive patient ... Key industry stakeholders are shifting focus away from ... results and effects of long-term specialty drug therapy ...
Breaking Medicine Technology:
(Date:6/20/2017)... Murfreesboro, Tennessee (PRWEB) , ... June 20, 2017 ... ... chronic care services, announced today that Claritas Capital, a Nashville-based private equity firm, ... to accelerate our expansion plans for some time, and Claritas Capital offers the ...
(Date:6/20/2017)... ... June 20, 2017 , ... Hayes, ... published a new eBook titled “ 5 Questions to Ask Before Entering the ... on the Genetic Test Evaluation (GTE) team, the book explores the various types ...
(Date:6/20/2017)... ... June 20, 2017 , ... AMC Health , ... and success in the clinical trials market. Similar to its approach in demonstrating positive ... the clinical trials marketplace by proving the value of eVisits to support virtual studies. ...
(Date:6/20/2017)... ... June 20, 2017 , ... With certifications and experience that ... Denville, NJ, Drs. Adam and Hal Kimowitz are currently accepting new patients at their ... orthodontics can cause for some patients, which is why they offer the latest in ...
(Date:6/20/2017)... ... 20, 2017 , ... Uniform Advantage (UA), a multi-channel retailer of ... to create tailored looks and athleisure-inspired outfits. UA Flex fabric is breathable, wrinkle resistant ... , With trendy looks hitting the medical community, UA Flex is for the medical ...
Breaking Medicine News(10 mins):